Article: Nicotinamide Riboside Improves Mobility in Mitochondrial DNA Disease: Clinical Findings

Sep 15, 2026 Clinical Mitochondrial Disease Mitochondrial Health Muscle Health

Nicotinamide Riboside Improves Mobility in Mitochondrial DNA Disease: Clinical Findings

Objectives

To evaluate safety, physical function, and mitochondrial responses to NR supplementation.

Journal

Genome Medicine

Key Outcomes

NR supplementation significantly, but minimally, improved the timed "up and go" test from 11.9 to 9.96 seconds.
NR tended to improve measures of mitochondrial function in muscle, most prominently in those with large-scale mitochondrial DNA deletions. Several muscle measurements moved in a direction consistent with improved mitochondrial function and a lower proportion of deleted mitochondrial DNA.

Duration

4 weeks

Dose

1250 to 2000 mg

Study Design

Open-label, single-arm exploratory study in 8 adults with genetically confirmed heteroplasmic mitochondrial DNA (mtDNA) disease.

Diagnoses were either with mutations at m.3243A>G/T or single large-scale mtDNA deletion.

See Published Study

Clinical

Effects of Nicotinamide Riboside in Mild Cognitive Impairment: Clinical Findings

Objectives To assess the safety and preliminary effects of NR supplementation on cognition, brain blood flow, and vascular function. Journal Alzheimer's & Dementia Key Outcomes NR increased b...